Signaling pathways in cranial chondrosarcoma: potential molecular targets for directed chemotherapy

被引:13
作者
Bloch, Orin [1 ]
Sughrue, Michael E. [1 ]
Mills, Steven A. [1 ]
Parsa, Andrew T. [1 ]
机构
[1] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA
关键词
Cranial chondrosarcoma; Integrin alpha v beta 3; Matrix metalloproteinase; PI3K pathway; PPAR-gamma; ACTIVATED-RECEPTOR-GAMMA; B-DEPENDENT PATHWAY; ALPHA-V-BETA-3; INTEGRIN; CANCER PROGRESSION; MATRIX METALLOPROTEINASES; DIFFERENTIATION MARKERS; BASE CHONDROSARCOMAS; INCREASES MIGRATION; MMP-13; EXPRESSION; TISSUE INHIBITOR;
D O I
10.1016/j.jocn.2010.09.025
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Cranial chondrosarcoma is an indolent tumor of the skull base, which is difficult to treat due to its inaccessible location. The current mainstay of treatment is surgical resection followed by adjuvant radiation therapy. To date, chemotherapy has been largely ineffective for chondrosarcoma due to a lack of targeted therapies. This review highlights numerous active signaling pathways that have been described in human chondrosarcoma. A limited number of functional experiments suggest that integrin activation at the cell surface results in upregulation of matrix metalloproteinases and extracellular matrix degradation, leading to increased tumor cell migration. This pathway appears to be dependent on phosphoinositide-3 kinase and MEK-extracellular signal-regulated kinase (ERK) signaling. Additionally, chondrosarcoma cell proliferation and degradation is dependent on peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activity, with a loss of PPAR-gamma expression and associated apoptosis in high-grade tumors. The data suggest that targeting these pathways may improve control of cranial chondrosarcoma and decrease the need for hazardous recurrent operations. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:881 / 885
页数:5
相关论文
共 61 条
[1]  
ALBELDA SM, 1990, CANCER RES, V50, P6757
[2]   Association between ratio of matrix metalloproteinase-1 to tissue inhibitor of metalloproteinase-1 and local recurrence, metastasis, and survival in human chondrosarcoma [J].
Berend, KR ;
Toth, AP ;
Harrelson, JM ;
Layfield, LJ ;
Hey, LA ;
Scully, SP .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1998, 80A (01) :11-17
[3]   Cranial Chondrosarcoma and Recurrence [J].
Bloch, Orin G. ;
Jian, Brian J. ;
Yang, Isaac ;
Han, Seunggu J. ;
Aranda, Derick ;
Ahn, Brian J. ;
Parsa, Andrew T. .
SKULL BASE-AN INTERDISCIPLINARY APPROACH, 2010, 20 (03) :149-156
[4]   A systematic review of intracranial chondrosarcoma and survival [J].
Bloch, Orin G. ;
Jian, Brian J. ;
Yang, Isaac ;
Han, Seunggu J. ;
Aranda, Derick ;
Ahn, Brian J. ;
Parsa, Andrew T. .
JOURNAL OF CLINICAL NEUROSCIENCE, 2009, 16 (12) :1547-1551
[5]   The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver [J].
Borbath, I. ;
Leclercq, I. ;
Moulin, P. ;
Sempoux, C. ;
Horsmans, Y. .
EUROPEAN JOURNAL OF CANCER, 2007, 43 (11) :1755-1763
[6]   INTEGRIN ALPHA(V)BETA(3) ANTAGONISTS PROMOTE TUMOR-REGRESSION BY INDUCING APOPTOSIS OF ANGIOGENIC BLOOD-VESSELS [J].
BROOKS, PC ;
MONTGOMERY, AMP ;
ROSENFELD, M ;
REISFELD, RA ;
HU, TH ;
KLIER, G ;
CHERESH, DA .
CELL, 1994, 79 (07) :1157-1164
[7]   Peroxisome proliferator-activated receptor-γ antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines [J].
Burton, Jack D. ;
Castillo, Mary E. ;
Goldenberg, David M. ;
Blumenthal, Rosalyn D. .
ANTI-CANCER DRUGS, 2007, 18 (05) :525-534
[8]   Update on chondrosarcomas [J].
Chow, Warren A. .
CURRENT OPINION IN ONCOLOGY, 2007, 19 (04) :371-376
[9]   INTRACRANIAL MALIGNANT CARTILAGINOUS TUMORS - REPORT OF 2 CASES AND REVIEW OF LITERATURE [J].
CIANFRIGLIA, F ;
POMPILI, A ;
OCCHIPINTI, E .
ACTA NEUROCHIRURGICA, 1978, 45 (1-2) :163-175
[10]   The role of αvβ3 in prostate cancer progression [J].
Cooper, CR ;
Chay, CH ;
Pienta, KJ .
NEOPLASIA, 2002, 4 (03) :191-194